Cytokinetics to Hold Annual Meeting of Stockholders
May 13 2015 - 4:00PM
Cytokinetics, Incorporated (Nasdaq:CYTK) announced today that its
Annual Meeting of Stockholders will be held on Wednesday, May 20,
2015 at 10:30 AM Pacific Time at the Embassy Suites Hotel, located
at 250 Gateway Boulevard in South San Francisco, CA. Robert I.
Blum, President and Chief Executive Officer, is scheduled to
present an overview of Cytokinetics' performance.
Interested parties may access the live audio webcast of this
presentation and replay by visiting the Investor Relations section
of the Cytokinetics website at www.cytokinetics.com. The live
conference call may also be accessed by dialing (866) 999-CYTK
(2985) (United States and Canada) or (706) 679-3078 (international)
and typing in the passcode 34785263. The webcast will be available
via Cytokinetics' website for one week following the
event. The replay of the audiocast will be available via
telephone from May 20, 2015 at 1:30 PM Pacific Time until May 27,
2015 by dialing (855) 859-2056 (United States and Canada) or (404)
537-3406 (international) and typing in the passcode 34785263.
About Cytokinetics
Cytokinetics is a clinical-stage biopharmaceutical company
focused on the discovery and development of novel small molecule
therapeutics that modulate muscle function for the potential
treatment of serious diseases and medical conditions. Cytokinetics
is developing tirasemtiv, a fast skeletal muscle activator, as a
potential treatment for amyotrophic lateral sclerosis (ALS).
Tirasemtiv has been granted orphan drug designation and fast track
status by the U.S. Food and Drug Administration and orphan
medicinal product designation by the European Medicines Agency for
the potential treatment of ALS. Cytokinetics is collaborating with
Amgen Inc. to develop omecamtiv mecarbil, a cardiac muscle
activator, for the potential treatment of heart failure.
Cytokinetics is collaborating with Astellas Pharma Inc. to develop
CK-2127107, a fast skeletal muscle activator, for the potential
treatment of spinal muscular atrophy. Amgen holds an exclusive
license worldwide to develop and commercialize omecamtiv mecarbil
and Astellas holds an exclusive license worldwide to develop and
commercialize CK-2127107. Both licenses are subject to
Cytokinetics' specified development and commercialization
participation rights. All of these drug candidates have arisen from
Cytokinetics' muscle biology focused research activities and are
directed towards the cytoskeleton. The cytoskeleton is a complex
biological infrastructure that plays a fundamental role within
every human cell. Additional information about Cytokinetics can be
obtained at http://www.cytokinetics.com/.
This press release contains forward-looking statements for
purposes of the Private Securities Litigation Reform Act of 1995
(the "Act"). Cytokinetics disclaims any intent or obligation to
update these forward-looking statements, and claims the protection
of the Act's safe harbor for forward-looking statements. Examples
of such statements include, but are not limited to, statements
relating to planned presentations, and the properties and potential
benefits of Cytokinetics' drug candidates and potential drug
candidates. Such statements are based on management's current
expectations, but actual results may differ materially due to
various risks and uncertainties, including, but not limited to,
potential difficulties or delays in the development, testing,
regulatory approval and production of Cytokinetics' drug candidates
and potential drug candidates that could slow or prevent clinical
development or product approval, including risks that current and
past results of clinical trials or preclinical studies may not be
indicative of future clinical trials results and that Cytokinetics'
drug candidates and potential drug candidates may have unexpected
adverse side effects or inadequate therapeutic efficacy. For
further information regarding these and other risks related to
Cytokinetics' business, investors should consult Cytokinetics'
filings with the Securities and Exchange Commission.
CONTACT: Cytokinetics, Incorporated
Joanna L. Goldstein (Investors & Media)
(650) 624-3000
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Mar 2024 to Apr 2024
Cytokinetics (NASDAQ:CYTK)
Historical Stock Chart
From Apr 2023 to Apr 2024